JERUSALEM, April 6, 2017 /PRNewswire/ --
- Zytecur™ products are first cannabis-based solutions to comply with U.S. Food & Drug Administration (FDA) regulations through CRADA and the U.S. Veterans Administration
- Partnerships in Israel leverage exclusive Israeli know-how in cannabis R&D
- Products that alleviate numerous health concerns, including epilepsy and cancer, available immediately online
- Chris Clark: "God led me to enter the medical cannabis market, conquer it, and use the proceeds to build the Kingdom of Christ"
Zytecur™, the only company in the United States currently conducting research and development on its product lines through pre-clinical models with a U.S. Federal Agency, has entered into joint ventures and affiliated partnerships with several Israeli bio-tech companies to offer cannabis-based solutions for a range of endemic global health concerns.
Zytecur™ is a product line that evolved from advanced research and development by IlanBio Cultures, Ltd., an American-Israeli operated corporation with headquarters in Hollister, California, and Tel Aviv, Israel.
Zytecur™ is working towards 'full-certification' with various U.S. agencies.
Dr. Rajvir Dahiya, Professor and Director of Urology at the University of California, San Francisco, Senior Research Career Scientist at the Department of Veterans Affairs and world renowned oncologist leads the study. Dr. Dahiya said, "Zytecur™ has signed America's first and only contract with the U.S. Government through a Cooperative Research and Development Agreement (CRADA) through the Veterans Affairs Medical Center, U.S. Department of Veteran Affairs. Zytecur™ product lines are tested through pre-clinical trials for cannabis extracts in the United States as a treatment for various cancer types with a U.S. Federal Agency."
The executed CRADA will make Zytecur™ compliant with the research protocols of the Food and Drug Administration, Drug Enforcement Administration, Health and Human Services National Institute of Health and National Institute of Drug Abuse regulations.
Zytecur™ products are available immediately and are sold on-line here. They include: Zytecur Pure for Pain and Inflammation, Zytecur Sleep for Insomnia, Zytecur Harmony for Epilepsy, Zytecur Calm for Anxiety and Zytecur Relief for Post-Traumatic Stress Disorder (P.T.S.D.), with Zytecur Cancer listed as coming soon after trials with the Federal Government are finalized.
Through its partnerships and subsidiaries, Zytecur™ is able to control all life-cycles of the cannabis plant. From seed genetics, breeding, live tissue culture propagation and pharmaceutical grade processing, Zytecur™ offers formulated, consistent, and effective products for our health conscious, environmentally minded benefactors.
Zytecur's main partner is IlanBio Cultures, an Israeli agro-biotechnology company at the forefront of large scale in vitro plant propagation cloning. The company has developed a highly efficient system for the establishment, multiplication and acclimatization of uniform, disease-free elite tissue culture plants through an automated, biologically controlled micro-propagation system in liquid bioreactor cultures.
Liam Gal-On, CEO and founder of IlanBio, said he partnered with the Zytecur™ team to "ensure high quality raw materials from plants that are pesticide free and cultivated with uniform and consistent ingredients. IlanBio's support assures Zytecur™ products will be produced under GAP standards and with high quality cannabis extracts. Our technology is a game changer in the agriculture space, supplying virus free and bacteria free plants with consistent, uniform results."
Israel's CanBreed is an affiliate partner seed company utilizing modern breeding and new genome editing technologies to solve the cultivation needs of pharmaceutical grade cannabis cultivators. CanBreed presents revolutionary seed genetics technology, set to disrupt the dangerous practices of global seed conglomerates such as Monsanto.
Chris Clark, co-founder and Chairman of the Board of Zytecur, was an enlisted Marine and Force Reconnaissance operator (an elite U.S. Marine Corps unit) and Iraq War veteran. He was wounded in 2005 in the al-Anbar province and received a Purple Heart Medal. He is a Stanford University alum, a former business professional at Goldman Sachs, and has experience in Silicon Valley.
Clark and his partners in Zytecur are all followers of Christ, as well as U.S. Marine Corps combat veterans who served in the Special Operations in the Iraq war. A portion of all profits from Zytecur™ will be allocated to further R&D taking place at the U.S. Veterans Administration to fight the world's deadliest diseases, as well as to Christian-based organizations that support their mission.
For further information/interviews with Chris Clark, Zytecur CEO, contact Laura Kam, [email protected] .